Vectors and hosts with increased expression of HBCAG

ABSTRACT

The invention relates to vectors and hosts with increased expression of HBcAg.

FIELD OF THE INVENTION

The invention is in the field of molecular biology. In particular, the invention relates to new sequences and improved expression of hepatitis B core protein.

BACKGROUND OF THE INVENTION

Hepatitis B virus is the most thoroughly characterized pathogen of the hepatitis diseases. The hepatitis B virus is associated with a wide spectrum of liver disease, from a subclinical carrier state to accute hepatitis, chronic hepatitis, postnecrotic (posthepatitic) cirrhosis, and hepatocellular carcinoma. It also has a poorly understood association with several primary non-hepatic disorders including polyarteritis nodesa and other collagen vascular diseases, membraneous glomerulonephritis, essential mixed cryoglobulinemina and papular acrodermatitis of childhood. Hepatitis symptoms and signs vary from minor flu-like illnesses to fulminant, fatal liver failure.

Groups at risk for contracting hepatitis B virus include certain hospital and dentist staff (e.g., oncology, hemodialysis-transplantation, gastroenterology, intensive care units, diagnostic laboratories, and surgical units), staff in institutions for the mentally handicapped, patients receiving blood and blood products, drug addicts, male homosexuals, and the families of chronic carriers.

The infective "DANE" particle consists of an inner core plus an outer surface coat. The inner core contains DNA and DNA polymerase. The DNA replicates within the nuclei of infected hepatocytes. The core antigen (HBcAg) is associated with the viral inner core. It can be found in infected liver cells but is not detectable in serum except by special techniques which disrupt the DANE particle. The hepatitis B virus is present in the cytoplasm of parenchymal liver cells of individuals with hepatitis B and constitutes the infective virus. The core particle displays HBcAg. The core of this particle is found in the nucleus of parenchymal cells, but as it passes through the cytoplasm, it acquires a surface coat.

Antibody to the core antigen appears promptly in the blood of infected individuals and persists indefinitely. High titers of IgM anti-HBc is found in patients with accute disease and may be the only marker of accute hepatitis B in some situations.

Serological detection of anti-HBc is accepted diagnostic evidence of hepatitis B viral infection. Therefore, it is desirable to have substantial quantities of HBcAg for use as an immunogen in development of monoclonal and polyclonal antibodies to the HBcAg, for preparing vaccines, and for use in detection of the viral infection in patients.

SUMMARY OF THE INVENTION

The present invention provides new HBcAg sequences with improved expression. The invention also provides nucleotide sequences which enhance expression of HBcAg. The invention also provides new HBcAg protein sequences. In addition, the invention provides methods for increasing expression of HBcAg.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 Enzyme linked immunosorbent Assay (ELISA) data showing increased expression of HBcAg with sequences of the invention.

DETAILED DESCRIPTION

The present invention provides new HBcAg sequences and methods for increasing expression of HBcAg. When Sequence ID No: 1 is altered to include additional nucleotides between the ribosome binding site and start codon, (also referred to as the initiation codon), the expression level is about ten (10) times higher than the same sequence unmodified. When the modification involves changing the second codon (first codon after the start codon) from GAC to GCT, plus nucleotides between the ribosome binding site and first ATG codon, increases of about twenty-five (25) times higher expression are obtained over the native sequence.

The present invention also provides DNA molecules described in Sequence ID No: 3, Sequence ID No: 5, Sequence ID No: 7, Sequence ID No: 9, and Sequence ID No: 11.

The invention also provides hosts, and methods for increasing expression of HBcAg which comprises transforming a host with the disclosed sequences.

The invention also provides amino acid sequences described in Sequence ID No: 2, Sequence ID No: 4, Sequence ID No: 6, Sequence ID No: 8, Sequence ID No: 10, and Sequence ID No: 12 and kits comprising the sequences.

Sequence ID No: 1 is referred to as the "native" sequence. Preferably Sequence ID No: 1 has an eight base pair spacer between the ribosome binding site and start codon. Most preferably the eight base pair spacer is Sequence ID No: 14 (AACAGACC). Sequence ID No: 3 is the same as Sequence ID No: 1 (silent mutations from a G to A at bp 39 and a C to T at bp 249 are present). Preferably Sequence ID No: 3 has a 10 base pair spacer between the ribosome binding site and the start codon. Most preferably the ten base pair spacer is Sequence ID No: 13 (AACAGAATTC). Sequence ID No: 5 is the same as Sequence ID No: 1 but has the alterations of the second codon change, bp 467 changes from G to A and deletion of bp 468, causing a frameshift. Preferably Sequence ID No: 5 has a ten base pair spacer between the ribosome binding site and start codon. Most preferably the ten base pair spacer is Sequence ID No: 13. Sequence ID No: 7 is the same as Sequence ID No: 1 but has the second codon change. Preferably Sequence ID No: 7 has an eight base pair spacer between the ribosome binding site and start codon. Most preferably the eight base pair spacer is Sequence ID No: 14. Sequence ID No: 9 is the same as Sequence ID No: 7 with a transition at bp 359 from a T to a C (resulting in a Val to Ala change in the protein). Preferably Sequence ID No: 9 has a ten base pair spacer between the ribosome binding site and start codon. Most preferably the ten base pair spacer is Sequence ID No: 13. Sequence ID No: 11 is the same as Sequence ID No: 7 with alterations of the second codon change, and deletion of bp 455, causing a frameshift. Preferably an eight base pair spacer is between the ribosome binding site and start codon. Most preferably the eight base pair spacer is Sequence ID No: 14.

Sequence ID No: 2, 4, 6, 8, 10, and 12 are predicted HBcAg protein sequences of the invention. Sequence ID No: 1 encodes the protein of Sequence ID No: 2. Sequence ID No: 3 also encodes the protein sequence in Sequence ID No: 2 (or 4). Sequence ID No: 5 encodes the protein in Sequence ID No: 6. Sequence ID No: 7 encodes the protein in Sequence ID No: 8. Sequence ID No: 9 encodes the protein in Sequence ID No: 10 Sequence ID No: 11 encodes the protein in Sequence ID No: 12. Since many amino acids are selected by more than one codon (degeneracy), DNA sequences can vary without corresponding changes in the amino acid sequences.

Tables 1 through 11 depict nucleotide and amino acid sequences of the invention (nucleotide sequences left to right are 5' to 3' and amino acid sequences left to right are amino terminus to carboxy terminus).

                                      TABLE 1                                      __________________________________________________________________________     ATGGACATTG                                                                               ACCCTTATAA                                                                              AGAATTTGGA                                                                               GCTACTGTGG                                                                               AGTTACTCTC                                                                               GTTTTTGCCT                                                                                60                 TCTGACTTCT                                                                               TTCCTTCCGT                                                                              CAGAGATCTC                                                                               CTAGACACCG                                                                               CCTCAGCTCT                                                                               GTATCGGGAA                                                                               120                 GCCTTAGAGT                                                                               CTCCTGAGCA                                                                              TTGCTCACCT                                                                               CACCATACCG                                                                               CACTCAGGCA                                                                               AGCCATTCTC                                                                               180                 TGCTGGGGGG                                                                               AATTGATGAC                                                                              TCTAGCTACC                                                                               TGGGTGGGTA                                                                               ATAATTTGGA                                                                               AGATCCAGCA                                                                               240                 TCAAGGGACC                                                                               TAGTAGTCAA                                                                              TTATGTTAAT                                                                               ACTAACATGG                                                                               GTTTAAAAAT                                                                               TAGGCAACTA                                                                               300                 TTGTGGTTTC                                                                               ATATATCTTG                                                                              CCTTACTTTT                                                                               GGAAGAGAGA                                                                               CTGTACTTGA                                                                               ATATTTGGTC                                                                               360                 TCTTTCGGAG                                                                               TGTGGATTCG                                                                              CACTCCTCCA                                                                               GCCTATAGAC                                                                               CACCAAATGC                                                                               CCCTATCTTA                                                                               420                 TCAACACTTC                                                                               CGGAAACTAC                                                                              TGTTGTTAGA                                                                               CGACGGGACC                                                                               GAGGCAGGTC                                                                               CCCTAGAAGA                                                                               480                 AGAACTCCCT                                                                               CGCCTCGCAG                                                                              ACGCAGATCT                                                                               CAATCGCCGC                                                                               GTCGCAGAAG                                                                               ATCTCAATCT                                                                               540                 CGGGAATCTC                                                                               AATGTTAG                                         558                 __________________________________________________________________________

                                      TABLE 2                                      __________________________________________________________________________     ATGGACATTG                                                                               ACCCTTATAA                                                                              AGAATTTGGA                                                                               GCTACTGTAG                                                                               AGTTACTCTC                                                                               GTTTTTGCCT                                                                                60                 TCTGACTTCT                                                                               TTCCTTCCGT                                                                              CAGAGATCTC                                                                               CTAGACACCG                                                                               CCTCAGCTCT                                                                               GTATCGGGAA                                                                               120                 GCCTTAGAGT                                                                               CTCCTGAGCA                                                                              TTGCTCACCT                                                                               CACCATACCG                                                                               CACTCAGGCA                                                                               AGCCATTCTC                                                                               180                 TGCTGGGGGG                                                                               AATTGATGAC                                                                              TCTAGCTACC                                                                               TGGGTGGGTA                                                                               ATAATTTGGA                                                                               AGATCCAGCA                                                                               240                 TCAAGGGATC                                                                               TAGTAGTCAA                                                                              TTATGTTAAT                                                                               ACTAACATGG                                                                               GTTTAAAAAT                                                                               TAGGCAACTA                                                                               300                 TTGTGGTTTC                                                                               ATATATCTTG                                                                              CCTTACTTTT                                                                               GGAAGAGAGA                                                                               CTGTACTTGA                                                                               ATATTTGGCC                                                                               360                 TCTTTCGGAG                                                                               TGTGGATTCG                                                                              CACTCCTCCA                                                                               GCCTATAGAC                                                                               CACCAAATGC                                                                               CCCTATCTTA                                                                               420                 TCAACACTTC                                                                               CGGAAACTAC                                                                              TGTTGTTAGA                                                                               CGACGGGACC                                                                               GAGGCAGGTC                                                                               CCCTAGAAGA                                                                               480                 AGAACTCCCT                                                                               CGCCTCGCAG                                                                              ACGCAGATCT                                                                               CAATCGCCGC                                                                               GTCGCAGAAG                                                                               ATCTCAATCT                                                                               540                 CGGGAATCTC                                                                               AATGTTAG                                         558                 __________________________________________________________________________

                                      TABLE 3                                      __________________________________________________________________________     ATGGCTATTG                                                                               ACCCTTATAA                                                                              AGAATTTGGA                                                                               GCTACTGTGG                                                                               AGTTACTCTC                                                                               GTTTTTGCCT                                                                                60                 TCTGACTTCT                                                                               TTCCTTCCGT                                                                              CAGAGATCTC                                                                               CTAGACACCG                                                                               CCTCAGCTCT                                                                               GTATCGGGAA                                                                               120                 GCCTTAGAGT                                                                               CTCCTGAGCA                                                                              TTGCTCACCT                                                                               CACCATACCG                                                                               CACTCAGGCA                                                                               AGCCATTCTC                                                                               180                 TCGTGGGGGG                                                                               AATTGATGAC                                                                              TCTAGCTACC                                                                               TGGGTGGGTA                                                                               ATAATTTGGA                                                                               AGATCCAGCA                                                                               240                 TCAAGGGACC                                                                               TAGTAGTCAA                                                                              TTATGTTAAT                                                                               ACTAACATGG                                                                               GTTTAAAAAT                                                                               TAGGCAACTA                                                                               300                 TTGTGGTTTC                                                                               ATATATCTTG                                                                              CCTTACTTTT                                                                               GGAAGAGAGA                                                                               CTGTACTTGA                                                                               ATATTTGGTC                                                                               360                 TCTTTCGGAG                                                                               TGTGGATTCG                                                                              CACTCCTCCA                                                                               GCCTATAGAC                                                                               CACCAAATGC                                                                               CCCTATCTTA                                                                               420                 TCAACACTTC                                                                               CGGAAACTAC                                                                              TGTTGTTAGA                                                                               CGACGGGACC                                                                               GAGGCAATCC                                                                               CCTAGAAGAA                                                                               480                 GAACTCCCTC                                                                               GCCTCGCAGA                                                                              CGCAGATCTC                                                                               AATCGCCGCG                                                                               TCGCAGAAGA                                                                               TCTCAATCTC                                                                               540                 GGGAATCTCA                                                                               ATGTTAGAAG                                                                              CTTCCGACAA                                                                               AACCGCCTAC                                                                               TCTCTTCTAA                                                                               AAGTCGGACT                                                                               600                 ATGTCTAATT                                                                               TAGTCTTGCG                                                                              TCTTCGCCAG                                                                               ACTATTTTGT                                                                               CTTAA               645                 __________________________________________________________________________

                                      TABLE 4                                      __________________________________________________________________________     ATGGCTATTG                                                                               ACCCTTATAA                                                                              AGAATTTGGA                                                                               GCTACTGTGG                                                                               AGTTACTCTC                                                                               GTTTTTGCCT                                                                                60                 TCTGACTTCT                                                                               TTCCTTCCGT                                                                              CAGAGATCTC                                                                               CTAGACACCG                                                                               CCTCAGCTCT                                                                               GTATCGGGAA                                                                               120                 GCCTTAGAGT                                                                               CTCCTGAGCA                                                                              TTGCTCACCT                                                                               CACCATACCG                                                                               CACTCAGGCA                                                                               AGCCATTCTC                                                                               180                 TGCTGGGGGG                                                                               AATTGATGAC                                                                              TCTAGCTACC                                                                               TGGGTGGGTA                                                                               ATAATTTGGA                                                                               AGATCCAGCA                                                                               240                 TCAAGGGACC                                                                               TAGTAGTCAA                                                                              TTATGGTAAT                                                                               ACTAACATGG                                                                               GTTTAAAAAT                                                                               TAGGCAACTA                                                                               300                 TTGTGGTTTC                                                                               ATATATCTTG                                                                              CCTTACTTTT                                                                               GGAAGAGAGA                                                                               CTGTACTTGA                                                                               ATATTTGGTC                                                                               360                 TCTTTCGGAG                                                                               TGTGGATTCG                                                                              CACTCCTCCA                                                                               GCCTATAGAC                                                                               CACCAAATGC                                                                               CCCTATCTTA                                                                               420                 TCAACACTTC                                                                               CGGAAACTAC                                                                              TGTTGTTAGA                                                                               CGACGGGACC                                                                               GAGGCAGGTC                                                                               CCCTAGAAGA                                                                               480                 AGAACTCCCT                                                                               CGCCTCGCAG                                                                              ACGCAGATCT                                                                               CAATCGCCGC                                                                               GTCGCAGAAG                                                                               ATCTCAATCT                                                                               540                 CGGGAATCTC                                                                               AATGTTAG                                         558                 __________________________________________________________________________

                                      TABLE 5                                      __________________________________________________________________________     ATGGCTATTG                                                                               ACCCTTATAA                                                                              AGAATTTGGA                                                                               GCTACTGTGG                                                                               AGTTACTCTC                                                                               GTTTTTGCCT                                                                                60                 TCTGACTTCT                                                                               TTCCTTCCGT                                                                              CAGAGATCTC                                                                               CTAGACACCG                                                                               CCTCAGCTCT                                                                               GTATCGGGAA                                                                               120                 GCCTTAGAGT                                                                               CTCCTGAGCA                                                                              TTGCTCACCT                                                                               CACCATACCG                                                                               CACTCAGGCA                                                                               AGCCATTCTC                                                                               180                 TGCTGGGGGG                                                                               AATTGATGAC                                                                              TCTAGCTACC                                                                               TGGGTGGGTA                                                                               ATAATTTGGA                                                                               AGATCCAGCA                                                                               240                 TCAAGGGACC                                                                               TAGTAGTCAA                                                                              TTATGTTAAT                                                                               ACTAACATGG                                                                               GTTTAAAAAT                                                                               TAGGCAACTA                                                                               300                 TTGTGGTTTC                                                                               ATATATCTTG                                                                              CCTTACTTTT                                                                               GGAAGAGAGA                                                                               CTGTACTTGA                                                                               ATATTTGGCC                                                                               360                 TCTTTCGGAG                                                                               TGTGGATTCG                                                                              CACTCCTCCA                                                                               GCCTATAGAC                                                                               CACCAAATGC                                                                               CCCTATCTTA                                                                               420                 TCAACACTTC                                                                               CGGAAACTAC                                                                              TGTTGTTAGA                                                                               CGACGGGACC                                                                               GAGGCAGGTC                                                                               CCCTAGAAGA                                                                               480                 AGAACTCCCT                                                                               CGCCTCGCAG                                                                              ACGCAGATCT                                                                               CAATCGCCGC                                                                               GTCGCAGAAG                                                                               ATCTCAATCT                                                                               540                 CGGGAATCTC                                                                               AATGTTAG                                         558                 __________________________________________________________________________

                                      TABLE 6                                      __________________________________________________________________________     ATGGCTATTG                                                                               ACCCTTATAA                                                                              AGAATTTGGA                                                                               GCTACTGTGG                                                                               AGTTACTCTC                                                                               GTTTTTGCCT                                                                                60                 TCTGACTTCT                                                                               TTCCTTCCGT                                                                              CAGAGATCTC                                                                               CTAGACACCG                                                                               CCTCAGCTCT                                                                               GTATCGGGAA                                                                               120                 GCCTTAGAGT                                                                               CTCCTGAGCA                                                                              TTGCTCACCT                                                                               CACCATACCG                                                                               CACTCAGGCA                                                                               AGCCATTCTC                                                                               180                 TGCTGGGGGG                                                                               AATTGATGAC                                                                              TCTAGCTACC                                                                               TGGGTGGGTA                                                                               ATAATTTGGA                                                                               AGATCCAGCA                                                                               240                 TCAAGGGACC                                                                               TAGTAGTCAA                                                                              TTATGTTAAT                                                                               ACTAACATGG                                                                               GTTTAAAAAT                                                                               TAGGCAACTA                                                                               300                 TTGTGGTTTC                                                                               ATATATCTTG                                                                              CCTTACTTTT                                                                               GGAAGAGAGA                                                                               CTGTACTTGA                                                                               ATATTTGGTC                                                                               360                 TCTTTCGGAG                                                                               TGTGGATTCG                                                                              CACTCCTCCA                                                                               GCCTATAGAC                                                                               CACCAAATGC                                                                               CCCTATCTTA                                                                               420                 TCAACACTTC                                                                               CGGAAACTAC                                                                              TGTTGTTAGA                                                                               CGACGGACCG                                                                               AGGCAGGTCC                                                                               CCTAGAAGAA                                                                               480                 GAACTCCCTC                                                                               GCCTCGCAGA                                                                              CGCAGATCTC                                                                               AATCGCCGCG                                                                               TCGCAGAAGA                                                                               TCTCAATCTC                                                                               540                 GGGAATCTCA                                                                               ATGTTAGAAG                                                                              CTTCCGACAA                                                                               AACCGCCTAC                                                                               TCTCTTCTAA                                                                               AAGTCGGACT                                                                               600                 ATGTCTAATT                                                                               TAGTCTTGCG                                                                              TCTTCGCCAG                                                                               ACTATTTTGT                                                                               CTTAA               645                 __________________________________________________________________________

                                      TABLE 7                                      __________________________________________________________________________      ##STR1##                                                                       ##STR2##                                                                       ##STR3##                                                                       ##STR4##                                                                       ##STR5##                                                                       ##STR6##                                                                       ##STR7##                                                                       ##STR8##                                                                       ##STR9##                                                                       ##STR10##                                                                      ##STR11##                                                                      ##STR12##                                                                     __________________________________________________________________________

                                      TABLE 8                                      __________________________________________________________________________      ##STR13##                                                                      ##STR14##                                                                      ##STR15##                                                                      ##STR16##                                                                      ##STR17##                                                                      ##STR18##                                                                      ##STR19##                                                                      ##STR20##                                                                      ##STR21##                                                                      ##STR22##                                                                      ##STR23##                                                                      ##STR24##                                                                     __________________________________________________________________________

                                      TABLE 9                                      __________________________________________________________________________      ##STR25##                                                                      ##STR26##                                                                      ##STR27##                                                                      ##STR28##                                                                      ##STR29##                                                                      ##STR30##                                                                      ##STR31##                                                                      ##STR32##                                                                      ##STR33##                                                                      ##STR34##                                                                      ##STR35##                                                                      ##STR36##                                                                     __________________________________________________________________________

                                      TABLE 10                                     __________________________________________________________________________      ##STR37##                                                                      ##STR38##                                                                      ##STR39##                                                                      ##STR40##                                                                      ##STR41##                                                                      ##STR42##                                                                      ##STR43##                                                                      ##STR44##                                                                      ##STR45##                                                                      ##STR46##                                                                      ##STR47##                                                                      ##STR48##                                                                      ##STR49##                                                                      ##STR50##                                                                     __________________________________________________________________________

                                      TABLE 11                                     __________________________________________________________________________      ##STR51##                                                                      ##STR52##                                                                      ##STR53##                                                                      ##STR54##                                                                      ##STR55##                                                                      ##STR56##                                                                      ##STR57##                                                                      ##STR58##                                                                      ##STR59##                                                                      ##STR60##                                                                      ##STR61##                                                                      ##STR62##                                                                      ##STR63##                                                                      ##STR64##                                                                     __________________________________________________________________________

By only varying the number of bases (i.e., single nucleotides or base pairs referring to pairs of complementary nucleotides) between the ribosomal binding site and the start codon without the second codon change, an increase in expression is also obtainable. Preferably the spacing (i.e. spacer) between the ribosomal binding site and the start codon is between 8 and 20 nucleotides. Most preferably 10 to 15 nucleotides are between the ribosomal binding site and the start codon. Sequence ID No: 13 and Sequence ID No: 14 are good examples of a 10 base pair and 8 base pair spacer, respectively. The particular nucleotide composition chosen to vary the distance between the ribosomal binding site and the start codon can vary. Preferably the nucleotides are chosen to have a high degree of homology with the same region between the ribosomal binding sites and the start codons of the host organisms.

Although the particular modification of the present invention at the second codon utilizes GCT as the second codon, the particular modification of the second codon is not limited to only GCT. For example, any codon utilized by a large number of the host organisms can be engineered into the second codon region. Preferred E. coli codons in the second position are AAA, AGC, GCG, AAC, TCT, AAT, ACC, AGT, ACA, GCT, ACT, CAA, GCA, GAA, GGT and ATC. It is unexpected that varying the second codon alone results in increased expression. As evident from FIG. 1, changing the second codon results in a two-fold increase in expression over the native sequence.

Since the modification of the gene at the second codon is especially beneficial for enhancement and expression in the E. coli host, an E. coli host is preferred.

Although any single alteration of the invention (e.g., spacer between the ribosomal binding site and start codon, second codon change, and deletion of basepair 455 or 468) in the DNA molecule results in increased expression of about two (2) fold over the native sequence, if any two alterations are made in combination, about a ten (10) fold increase in expression is obtained. If all three alterations are made in combination, about a twenty-five (25) fold increase in expression is obtained. Importantly, the antigenicity of the HBcAg is not compromised by the alterations. Even the deletion of base pair 455 or 468, which creates a frame shift at the C-terminus of the HBcAg protein, does not alter the antigenicity of the protein.

Sequence ID No: 1 was originally amplified from an HBsAg positive plasma using appropriate primers and standard protocols. Now that the sequence is known, the HBcAg sequence can be prepared in a variety of ways and therefore is not limited to any particular preparation means.

For example, the nucleotide sequences of the invention can be prepared by use of recombinant DNA technology or, alternatively, by automated synthesis. The sequences of the invention can also be cloned in a suitable vector and amplified in a suitable host.

Also, sequences of the invention can be synthesized using commercially available methods and equipment. For example, the solid phase phosphotriester method can be used to produce the sequences of the invention. The sequences can be conveniently synthesized by the modified phosphotriester method using fully protected DNA building blocks. Such synthetic methods can be carried out in substantial accordance with the procedure of Itakura, et al., 1977, Science 198:1056 and Crea, et al., 1978, Proc. Nat. Acad. Sci. U.S.A., 75:575, and Narang, et al., 1980, Methods in Enzymology, 68:90. In addition to manual procedures the sequences can be synthesized using automated synthesizers.

Methods for solution and solid phase synthesis are widely known, and various commercially available automatic synthesizers can be used in accordance with known protocols. See, for example Stewart & Young, Solid Phase Peptide Synthesis 2d Edition, Pierce Chemical Company, 1984; Tam, et al., J. Am. Chem. Assoc. 105:6442 (1983) and Merrifield, et al., Biochemistry 21:5020 (1982), which are incorporated herein by reference. The sequences of the invention can be produced by a number of procedures, including synthetic DNA synthesis, cDNA cloning, genomic cloning, polymerase chain reaction (PCR) technology, or a combination or these approaches. See, e.g., Maniatis, MOLECULAR CLONING, A LABORATORY MANUAL, 1982. Mutagenesis procedures to produce "deletion mutants" that encode the desired sequence can also be employed. Procedures suitable for producing such mutants include polymerase chain reaction technology and variations thereof, or site specific mutagenesis procedures similar to those of Kunkel, Proc. Natl. Acad. Sci. USA 82:488 (1985) or Eckstein, et al., Nucleic Acids Res. 13:8764 (1985).

For cloning, a selected DNA sequence of the invention will be inserted into a suitable vector. A number of suitable vectors may be used, including cosmids, plasmids, bacteriophage and viruses. The principal requirements for such a vector are that it be capable of reproducing itself and stably transforming a host cell. Most preferably, the vector will comprise an "expression vector" which is capable of directing "expression" or cellular production of a peptide encoded by the DNA sequence of the invention. Typical expression vectors comprise a promoter region, a 5' untranslated region, a coding sequence, a 3' untranslated region, an origin of replication, a selective marker and a transcription termination site.

Suitable vectors for use in practicing the invention include pKK233-2 (Pharmacia), pKK223-2 (Pharmacia), pTTQ18 (Amersham, Arlington Heights, Ill.), pBTacl (Boehringer Mannheim), pET expression systems (Novagen, Madison, Wis.), and pPL-λ (Pharmacia).

Promoters for use in expression vectors include, lactose (lac) control elements, lambda (PL) control elements, arabinose control elements, tryptophan (trp) control elements, and hybrids thereof. In addition, the vector may contain any one of a number of various markers facilitating selection of a transformed host cell. Such markers include genes associated with temperature sensitivity, drug resistance (e.g., resistance to ampicillin, chloramphenicol or tetracycline), or enzymes associated with visual characeristics of the host organism.

The vector may be prepared for insertion of the DNA sequence in a number of ways. Most simply, both the DNA sequence and the vector are digested with an appropriate set of restriction enzymes to generate sites suitable for ligation of the selected DNA sequence into the vector in an orientation and position suitable to allow expression of the peptide encoded by the sequence. Then, the DNA sequence is integrated into the vector by any of a number of suitable procedures, including treatment with a selected ligase.

After the sequence has been integrated into the vector, the vector may be used to transform a host cell. In general, the host cell may comprise any cellular organism including a prokaryotic cell or eukaryotic cell that is transformed with or competent of becoming transformed with the vector comprising the sequences of the present invention. Suitable host cells include, for example, bacterial cells such as E. coli or B. subtilis, mammalian cells (Kaufman, High Level Production of Proteins in Mammalian Cells, Genetic Engineering Principles and Methods, ed. J. K. Setlow Plenum Press, 9:155, 1988), yeast (Barr, et al., Yeast Genetic Engineering, eds. Butterworth, Boston, 1989), and insect cells (Maeda, Expression of Foreign Genes in Insects using Baculovius Vectors, T. E. Mittler eds. Annual Review of Entomology 34:351, 1989). A number of transformation techniques suitable for use with the particular vector-host cell combination may be employed. See, e.g., Maniatis, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratories (1982).

For production of HBcAg product, the transformed host cell is cultured in a suitable medium under conditions designed to allow maximal expression with the particular combination of host and vector employed. By transforming hosts with sequences of the invention, greater amounts of HBcAg product is obtained.

Sequences of the invention can be used in methods and kits designed to detect the presence of antibodies in humans and therefore recognize Hepatitis B virus (HBV) infected humans and blood samples which have been infected by the hepatitis virus.

For example, the HBcAg produced by hosts transformed by recombinant DNA molecules of this invention or synthetically, can be used in the immunological diagnostic tests currently available for hepatitis B virus detection, such as radioimmunoassay or ELISA (enzyme linked immunosorbent assay). In one type of radioimmunoassay anti-core antigen antibody, raised in a laboratory animal, is attached to a solid phase, such as the inside of a test tube. HBcAg is then added to the tube so it can bind with the antibody. To the tube coated with the antigen-antibody complex is added a sample of the patient's serum, together with a known amount of HBV anti-core antibody labelled with a radioactive isotope such as radioactive iodine. Any HBV antibody in the patient's serum will compete with the labelled antibody for the free binding sites on the antigen-antibody complex. Once the serum has been allowed to interact, the excess liquid is removed, the test tube washed, and the amount of radioactivity measured. A positive result (i.e., that the patient's serum contains HBV antibody) is indicated by a low radioactive count. In one type of ELISA test, a microtitre plate is coated with HBcAg and a sample of a patient's serum is added. After a period of incubation permitting interaction of any antibody with the antigen, the plate is washed and a preparation of anti-human antibodies, raised in a laboratory animal, and which are linked to an enzyme label, is added, incubated to allow reaction to take place, and the plate rewashed. Thereafter, enzyme substrate is added to the microtitre plate and incubated for a period of time to allow the enzyme to work on the substrate, and the adsorbance of the final preparation is measured. A large change in adsorbance indicates a positive result.

The following examples illustrate the specific embodiments of the invention described in this document. As would be apparent to skilled artisans, various changes and modifications are possible and are contemplated within the scope of the invention described.

EXAMPLES Materials and Preparation Amplification of Core Gene

Polymerase chain reactions (PCR) are set up as follows:

    ______________________________________                                         H.sub.2 O              21.5   μl                                            PCR 10X Buffer*        10.0   μl                                            1.25 mM dNTPs          16.0   μl                                            20 μM Forward Primer                                                                               1.0    μl                                            20 μM Reverse Primer                                                                               1.0    μl                                            HBV DNA                50.0   μl                                            P/E Amplitaq           0.5    μl                                                                   100.0  μl                                            *PCR 10X Buffer:                                                                              30 cycles:                                                                              95 degrees C. - 2.0 minutes                            500 mM KCl              50 degrees C. - 1.5 minutes                            100 mM Tris-HCl (pH 8.3)                                                                               72 degrees C. - 1.5 minutes                            15 mM MgCl.sub.2                                                               0.1% gelatin                                                                   ______________________________________                                    

Oligonucleotide Primer Design and Synthesis

Oligonucleotide primers are synthesized on an Applied Biosystems, Inc. (ABI) DNA Synthesizer Model 381-A (Foster City, Calif.), or equivalent, according to manufacturer's specifications. "Trityl-On" oligonucleotides are purified using ABI "OPC" purification columns or equivalent according to manufacturer's protocol. One ml of eluent is dried in a Savant Speed-Vac, or equivalent, and resuspended in 100 μl of 10 mM Tris-HCl (pH 7.2), 1 mM EDTA. A 20 μM Stock solution of each primer is made for use in the PCR.

The following is the list of oligo primers for amplifying the core gene for cloning and expression.

    __________________________________________________________________________     Forward primers for expression in pKK233                                       "native"                                                                              (Seq ID No: 15) GGCC ATG GAC ATT GAC CCT TAT AAA                        2nd codon                                                                              ##STR65##                                                                     GGA                                                                     Forward primers for expression in pKK223                                              EcoRI                                                                   10 bp spacer                                                                          (Seq ID No: 17) CCGAATTC ATG GAC ATT GAC CCT TAT AAA                    2nd + 10 bp                                                                            ##STR66##                                                              11 bp  (Seq ID No: 19) CGGAATTCG ATG GAC ATT GAC CCT TAT AAA                   12 bp  (Seq ID No: 20) CGGAATTCGG ATG GAC ATT GAC CCT TAT AAA                  13 bp  (Seq ID No: 21) CGGAATTCGGA ATG GAC ATT GAC CCT TAT AAA                 14 bp  (Seq ID No: 22) CGGAATTCGGAT ATG GAC ATT GAC CCT TAT AAA                15 bp  (Seq ID No: 23) CGGGAATTCGGATC ATG GAC ATT GAC CCT TAT AAA              Reverse primer for both pKK233 and pKK223                                             HindIII                                                                        (Seq ID No: 24) GGAAGCTT CTA ACA TTG AGA TTC CCG AGA TTG                       AGA TCT TCT GCG                                                         __________________________________________________________________________

EXAMPLE 1 Isolation of Hepatitis B DNA

Using a protocol in substantial accordance with I. Baginski, et. al. "Detection of Hepatitis B Virus", In PCR Protocols, edited by M. A. Innis, D. H. Gelfand, J. J. Sninsky and T. J. White, 348-355, Academic Press, Inc. (1990). Hepatitis B virus (HBV) DNA is isolated from an HBsAg positive serum (sample #2791-19A obtained from Interstate Blood Bank, Inc., Memphis, Tenn.) as follows:

To about 60 μl of HBsAg positive serum is added about 75 μl of 250 μg/ml proteinase K (Boehringer Mannheim, Indianapolis, Ind.) in: 0.25% SDS, 5 mM EDTA, 10 mM Tris-HCl (pH 8.0). This solution is incubated for about 2 hours at about 56 degrees C. The proteinase K is then heat inactivated at about 95 degrees C. for about 10 minutes. The total volume is brought to 1215 μl in 1X Taq Polymerase buffer: 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 2.5 mM MgCl₂, 0.01% gelatin (w/v), 0.5% Tween 20, 0.5% NP 40. Fifty microliters of this prepared DNA is used in subsequent polymerase chain reactions (PCRs) for generating HBcAg clones.

EXAMPLE 2 Cloning of Amplified HBcAg Gene Fragment

A PCR is set up using primers Sequence ID No: 15 and Sequence ID No: 24 to generate the first core gene fragment to be cloned. The resulting ˜570 bp fragment and the expression vector pKK233-2 (Pharmacia) are doubly digested with NcoI/HindIII (BRL). A ligation is set up with T4 ligase (BRL). Using a method in substantial accordance witin the teaching of D. H. Hanahan, "Techniques for Transformation of E. coli", In DNA cloning volume I, a practical approach, edited by D. M. Glover, 109, IRL Press Limited (1985), frozen competent E. coli strain XL1Blue (Stratagene) is transformed with the ligation, spreading 100 μl of the transformation mix on LB (100 μg/ml ampicillin) plates. Transformants are screened for inserts and those containing the desired fragment are used in expression experiments.

EXAMPLE 3 Expression of Core Protein

Cultures (12.5 ml) LB (100 μg/ml ampicillin) are grown to mid log then induced with isopropylthio-β-D-galactoside (IPTG) to a final concentration of 1 mM. Cultures are allowed to grow overnight, approximately 16 hours. 1.5 ml of the culture is removed, spun down at full speed in a Brinkman microfuge or equivalent. The pellet is resuspended in 100 μl 1X sample prep buffer (U. K. Laemmli, Nature 227:680 (1970), boiled about 5 minutes and 10 μl run on a 12% SDS PAGE gel at 40 mA for about 11/4 hour. A Western blot is prepared by transferring proteins from the gel to Immobilon-P membrane (Millipore, Bedford, Mass.), or equivalent at 100 mA in a Hoefer Semidry Transfer apparatus or equivalent for 1 hour using Towbin buffer (25 mM Tris (pH 8.3), 192 mM Glycine, 15% methanol). After transfer, membrane is blocked with 5% BSA in 1X Tris buffered saline (TBS) (10 mM Tris-HCl, (pH 8.0), 0.9% NaCl) for 30 minutes. An anti-HBcAg polyclonal antibody (this antibody solution in phosphate buffered saline (PBS)+a carrier protein, is a component of a kit, but is sold separately, this antibody concentration is unknown) (BioGenex Laboratories, Dublin, Calif.--catalog #PA082-5P) is incubated with the membrane for 1 hour. Membrane is washed 5X with TBS. Membrane was then incubated with a goat anti-rabbit horseradish peroxidase conjugated polyclonal antibody (Cappel Organonteknika, West Chester, Pa.) at 1:1000 in the 5% bovine serum albumin (BSA)/TBS solution for one hour. Membrane is washed 5X with TBS then developed with 4-chloro-1-naphthol and hydrogen peroxide. Clones expressing HBcAg show the appropriate size reactive band at ˜21 KDa. However, all show very low levels of expression.

EXAMPLE 4 Increasing Expression Levels

Oligonucleotide primers are synthesized (see "Materials and Preparations" above) to allow about 10 to 15 bp between the ribosome binding site and the ATG start codon. PCRs are set up with the following primer sets using the method previously described: Sequence ID No: 17--Sequence ID No: 24, Sequence ID No: 19--Sequence ID No: 24, Sequence ID No: 20--Sequence ID No: 24, Sequence ID No: 21--Sequence ID No: 24, Sequence ID No: 22--Sequence ID No: 24, and Sequence ID No: 23--Sequence ID No: 24. All PCRs generate the appropriate ˜570 bp fragment. These fragments are doubly digested with EcoRI and Hind III and directionally cloned into pKK223-3 (Pharmacia, Piscataway, N.J.) as described above. Transformations are set up as previously described.

LB plates are spread with 50 μl of 1M IPTG and a membrane sandwich placed on the surface of the agar. The sandwich is prepared by placing a nitrocellulose membrane (BA 85; Schleicher & Schuell, Inc., Keene, N.H.) or equivalent, on top of the agar medium and then a cellulose acetate membrane (OE67; Schleicher & Schuell), or equivalent, on top of that. Transformations are then plated as before and plates incubated at about 37 degrees C. overnight. The nitrocellulose filters are removed and blocked for about 1 hour in 5% BSA/TBS. An anti-HBcAg monoclonal antibody is added at 20 μg/ml and incubated for about 1 hour. Membranes are washed with TBS a secondary goat anti-mouse horseradish conjugated antibody (Cappel) is added at 1:2000 in 5% BSA/TBS for about 1 hour. Membranes are washed with TBS and developed with 4-chloro-1-naphthol and hydrogen peroxide. Reactive colonies are patched out for a second direct colony immunoblot (DCI) and again chosen for reactivity. The 10 bp spacer clones are chosen for further analysis and quantitation in a sandwich ELISA.

Two oligo primers Sequence ID No: 16 and Sequence ID No: 18 (see "materials and Preparation",) are designed to change the HBcAg second codon from GAC to GCT. Primer Sequence ID No: 16 changes the second codon with the fragment to be cloned into pKK233-2 while primer Sequence ID No: 18 allows for the 10 bp spacer as well as the second codon change. PCRs are set up and fragments cloned as previously mentioned. DCI are set up for screening transformants. Reactive colonies are chosen for further analysis and quantitation in a sandwich ELISA.

EXAMPLE 5 Quantitation for Increased Expression of HBcAg

Strains tested by ELISA

    ______________________________________                                         Strain       Vector     Fragment                                               ______________________________________                                         Sequence ID No: 1                                                                           pKK233-2   HBcAg DNA sequence                                     Sequence ID No: 3                                                                           pKK223-3   10 bp spacer                                           Sequence ID No: 5                                                                           Pkk223-3   10 bp spacer +                                                                 2nd codon change                                       Control      pKK223-3   No insert                                              ______________________________________                                    

3 ml overnight cultures (LB--100 μg/ml Ampicillin) of each of the above stains are grown at about 37 degrees C. 250 μl of the overnight culture (1:50) is used to inoculate 12.5 ml cultures (same medium). Cultures are grown to 0.6-0.8 A₆₀₀ then induced by adding 1M IPTG to ˜1 mM. Cultures are allowed to grow overnight (about 19 hours). One O.D. unit (A₆₀₀) of cells from each culture is removed and spun down and resuspended in 975 ul of PBS to which 10 μl of 10 μg/ml lysozyme (Sigma, St. Louis, Mo.) in PBS was added. Each is frozen in liquid nitrogen and thawed at about 37 degrees C. 3 times. 1M MgCl₂ is added to 5 mM (5 μl) and 10 μl of 1 mg/ml DNase (Sigma) is added and then the solution is incubated at room temperature for about 10 minutes. Lysates are spun at ˜7000 xg in microfuge for about 10 minutes. The supernatant fraction is removed and used in the ELISA.

One hundred microliters of "capture" antibody is coated onto plates at 20 μg/ml in phosphate buffered saline (PBS) (10 mM Phosphate (pH 7.2), 130 mM NaCl) at about 4 degrees C. overnight. Capture antibody solution is removed and the wells blocked with 2.5% BSA in PBS for about 1 hour. Fifty microliters of serial two fold dilutions of E. coli lysates (in 2.5% BSA/PBS) from 1:8 down to 1:16,000 are placed in wells and incubated for about 1 hour. Wells are washed 5 times with PBS+0.05% Tween 20 (PBS-Tween). Fifty microliters of biotinylated detector antibody is added at 5 μg/ml in 2.5% BSA/PBS to each well and incubated for about 1 hour. Plates are washed 5 times with PBS-Tween. Fifty microliters of Avidin-HRP (1 mg/ml) (Sigma) diluted 1:2000 in 2.5% BSA/PBS are added to each well and incubated for about 1 hour. Plates are washed 5 times with PBS Tween, and developed with 50 μl of o-phenylenediamine dihydrochloride (OPD) (20 mg OPD, 100 mM citrate (pH 5.5), 7 μl 30% hydrogen peroxide). After two minutes the reaction is stopped by adding about 50 μl of 4.5M sulphuric acid. Plates are read at A₄₉₀. Relative quantities of HBcAg in each lysate is calculated against a standard curve generated with purified HBcAg from 20 μg to 0.02 ng per well (2 fold serial dilution).

Although the invention has been described with respect to specific modifications, the details thereof are not to be construed as limitations, for it will be apparent that various equivalents, changes and modifications may be resorted to without departing from the spirit and scope thereof, and it is understood that such equivalent embodiments are to be included therein.

    __________________________________________________________________________     SEQUENCELISTING                                                                (1) GENERAL INFORMATION:                                                       (iii) NUMBER OF SEQUENCES: 24                                                  (vi) CURRENT APPLICATION DATA:                                                 (A) APPLICATION NUMBER:                                                        (B) FILING DATE:                                                               (2) INFORMATION FOR SEQ ID NO:1:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 558 base pairs                                                     (B) TYPE: nucleic acid                                                         (C ) STRANDEDNESS: double                                                      (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..558                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                        ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTC48                             MetAspIleAspProTyrLysGluPheGl yAlaThrValGluLeuLeu                              151015                                                                         TCGTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTCCTAGAC96                             SerPheLeuProSerAspPhePheProS erValArgAspLeuLeuAsp                              202530                                                                         ACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGC144                            ThrAlaSerAlaLeuTyrArgGluAlaLeu GluSerProGluHisCys                              354045                                                                         TCACCTCACCATACCGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAA192                            SerProHisHisThrAlaLeuArgGlnAlaIleLeu CysTrpGlyGlu                              505560                                                                         TTGATGACTCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCA240                            LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspPr oAla                              65707580                                                                       TCAAGGGACCTAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAA288                            SerArgAspLeuValValAsnTyrValAsnThrAsnMetG lyLeuLys                              859095                                                                         ATTAGGCAACTATTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGA336                            IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThr PheGlyArg                              100105110                                                                      GAGACTGTACTTGAATATTTGGTCTCTTTCGGAGTGTGGATTCGCACT384                            GluThrValLeuGluTyrLeuValSerPheGlyValTrpIle ArgThr                              115120125                                                                      CCTCCAGCCTATAGACCACCAAATGCCCCTATCTTATCAACACTTCCG432                            ProProAlaTyrArgProProAsnAlaProIleLeuSerThrLeuPr o                              130135140                                                                      GAAACTACTGTTGTTAGACGACGGGACCGAGGCAGGTCCCCTAGAAGA480                            GluThrThrValValArgArgArgAspArgGlyArgSerProArgArg                               145 150155160                                                                  AGAACTCCCTCGCCTCGCAGACGCAGATCTCAATCGCCGCGTCGCAGA528                            ArgThrProSerProArgArgArgArgSerGlnSerProArgArgArg                                165170175                                                                     AGATCTCAATCTCGGGAATCTCAATGTTAG558                                              ArgSerGlnSerArgGluSerGlnCys                                                    180 185                                                                        (2) INFORMATION FOR SEQ ID NO:2:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 185 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                        MetAspIleAspProTyrLysGluPheGlyAlaThrValGluLeuLeu                               1 51015                                                                        SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ThrAlaSerAlaLeuTyrArgGlu AlaLeuGluSerProGluHisCys                              354045                                                                         SerProHisHisThrAlaLeuArgGlnAlaIleLeuCysTrpGlyGlu                               505560                                                                         LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       SerArgAspLeuValValAsnTyrValAsnThrAsnMetGlyLeuLys                                859095                                                                        IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100105110                                                                      GluThrValLeuG luTyrLeuValSerPheGlyValTrpIleArgThr                              115120125                                                                      ProProAlaTyrArgProProAsnAlaProIleLeuSerThrLeuPro                               130135 140                                                                     GluThrThrValValArgArgArgAspArgGlyArgSerProArgArg                               145150155160                                                                   ArgThrProSerProArgArgArgArgSerGlnSerPro ArgArgArg                              165170175                                                                      ArgSerGlnSerArgGluSerGlnCys                                                    180185                                                                         (2) INFORMATION FOR SEQ ID NO:3:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 558 base pairs                                                      (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..558                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                        ATGGACATTGACCCTTATAAAGAATTTGGAGCTACTGTAGAGTTACTC48                             MetAspIleAs pProTyrLysGluPheGlyAlaThrValGluLeuLeu                              151015                                                                         TCGTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTCCTAGAC96                             SerPheLeuP roSerAspPhePheProSerValArgAspLeuLeuAsp                              202530                                                                         ACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGC144                            ThrAlaSerAla LeuTyrArgGluAlaLeuGluSerProGluHisCys                              354045                                                                         TCACCTCACCATACCGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAA192                            SerProHisHisThrAla LeuArgGlnAlaIleLeuCysTrpGlyGlu                              505560                                                                         TTGATGACTCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCA240                            LeuMetThrLeuAlaThrTrpValGl yAsnAsnLeuGluAspProAla                              65707580                                                                       TCAAGGGATCTAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAA288                            SerArgAspLeuValValAsnT yrValAsnThrAsnMetGlyLeuLys                              859095                                                                         ATTAGGCAACTATTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGA336                            IleArgGlnLeuLeuTrpPhe HisIleSerCysLeuThrPheGlyArg                              100105110                                                                      GAGACTGTACTTGAATATTTGGCCTCTTTCGGAGTGTGGATTCGCACT384                            GluThrValLeuGluTyrLeuAla SerPheGlyValTrpIleArgThr                              115120125                                                                      CCTCCAGCCTATAGACCACCAAATGCCCCTATCTTATCAACACTTCCG432                            ProProAlaTyrArgProProAsnAlaPr oIleLeuSerThrLeuPro                              130135140                                                                      GAAACTACTGTTGTTAGACGACGGGACCGAGGCAGGTCCCCTAGAAGA480                            GluThrThrValValArgArgArgAspArgGlyArgS erProArgArg                              145150155160                                                                   AGAACTCCCTCGCCTCGCAGACGCAGATCTCAATCGCCGCGTCGCAGA528                            ArgThrProSerProArgArgArgArgSerGln SerProArgArgArg                              165170175                                                                      AGATCTCAATCTCGGGAATCTCAATGTTAG558                                              ArgSerGlnSerArgGluSerGlnCys                                                     180185                                                                        (2) INFORMATION FOR SEQ ID NO:4:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 185 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                        MetAspIleAspProTyrLysGluPheGlyAlaThrValGluLe uLeu                              151015                                                                         SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ThrAla SerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                              354045                                                                         SerProHisHisThrAlaLeuArgGlnAlaIleLeuCysTrpGlyGlu                               50 5560                                                                        LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       SerArgAspLeuValValAsnTyrValAsnThr AsnMetGlyLeuLys                              859095                                                                         IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100105 110                                                                     GluThrValLeuGluTyrLeuAlaSerPheGlyValTrpIleArgThr                               115120125                                                                      ProProAlaTyrArgProProAsnAlaProIleLeuSerThrLeuPro                               130 135140                                                                     GluThrThrValValArgArgArgAspArgGlyArgSerProArgArg                               145150155160                                                                   ArgThrProSerProArgArg ArgArgSerGlnSerProArgArgArg                              165170175                                                                      ArgSerGlnSerArgGluSerGlnCys                                                    180185                                                                         (2) INFORMATION FOR SEQ ID NO:5:                                               (i) SEQUENCE CHARACTERISTICS:                                                   (A) LENGTH: 645 base pairs                                                    (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..645                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                        ATGGCTATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTC 48                            MetAlaIleAspProTyrLysGluPheGlyAlaThrValGluLeuLeu                               151015                                                                         TCGTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTCCTAGAC 96                            SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGC 144                           ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         TCACCTCACCATACCGCACTCAGGCAAGCCATTCTCTCGTGGGGGGAA192                             SerProHisHisThrAlaLeuArgGlnAlaIleLeuSerTrpGlyGlu                              505560                                                                         TTGATGACTCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCA240                            LeuMetTh rLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                              65707580                                                                       TCAAGGGACCTAGTAGTCAATTATGTTAATACTAACATGGGTTTAAAA288                            SerA rgAspLeuValValAsnTyrValAsnThrAsnMetGlyLeuLys                              859095                                                                         ATTAGGCAACTATTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGA336                            Ile ArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                              100105110                                                                      GAGACTGTACTTGAATATTTGGTCTCTTTCGGAGTGTGGATTCGCACT384                            GluThr ValLeuGluTyrLeuValSerPheGlyValTrpIleArgThr                              115120125                                                                      CCTCCAGCCTATAGACCACCAAATGCCCCTATCTTATCAACACTTCCG432                            ProProAlaTy rArgProProAsnAlaProIleLeuSerThrLeuPro                              130135140                                                                      GAAACTACTGTTGTTAGACGACGGGACCGAGGCAATCCCCTAGAAGAA480                            GluThrThrValValArgA rgArgAspArgGlyAsnProLeuGluGlu                              145150155160                                                                   GAACTCCCTCGCCTCGCAGACGCAGATCTCAATCGCCGCGTCGCAGAA528                            GluLeuProArgLeu AlaAspAlaAspLeuAsnArgArgValAlaGlu                              165170175                                                                      GATCTCAATCTCGGGAATCTCAATGTTAGAAGCTTCCGACAAAACCGC576                            AspLeuAsnLeuGly AsnLeuAsnValArgSerPheArgGlnAsnArg                              180185190                                                                      CTACTCTCTTCTAAAAGTCGGACTATGTCTAATTTAGTCTTGCGTCTT624                            LeuLeuSerSerLysSe rArgThrMetSerAsnLeuValLeuArgLeu                              195200205                                                                      CGCCAGACTATTTTGTCTTAA645                                                       ArgGlnThrIleLeuSer                                                              210215                                                                        (2) INFORMATION FOR SEQ ID NO:6:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 214 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                        MetAlaIleAspProTyrLysGluPheGlyAlaThrValGluLeuLeu                                151015                                                                        SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ThrAlaSerAl aLeuTyrArgGluAlaLeuGluSerProGluHisCys                              354045                                                                         SerProHisHisThrAlaLeuArgGlnAlaIleLeuSerTrpGlyGlu                               5055 60                                                                        LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       SerArgAspLeuValValAsnTyrValAsnThrAsnM etGlyLeuLys                              859095                                                                         IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100105110                                                                       GluThrValLeuGluTyrLeuValSerPheGlyValTrpIleArgThr                              115120125                                                                      ProProAlaTyrArgProProAsnAlaProIleLeuSerThrLeuPro                               130 135140                                                                     GluThrThrValValArgArgArgAspArgGlyAsnProLeuGluGlu                               145150155160                                                                   GluLeuProArgLeuAlaAspAlaAs pLeuAsnArgArgValAlaGlu                              165170175                                                                      AspLeuAsnLeuGlyAsnLeuAsnValArgSerPheArgGlnAsnArg                               180185 190                                                                     LeuLeuSerSerLysSerArgThrMetSerAsnLeuValLeuArgLeu                               195200205                                                                      ArgGlnThrIleLeuSer                                                             210                                                                            (2) INFORMATION FOR SEQ ID NO:7:                                               (i) SEQUENCE CHARACTERISTICS:                                                   (A) LENGTH: 558 base pairs                                                    (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..558                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                        ATGGCTATTGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTC 48                            MetAlaIleAspProTyrLysGluPheGlyAlaThrValGluLeuLeu                               151015                                                                         TCGTTTTTGCCTTCTGACTTCTTTCCTTCCGTCAGAGATCTCCTAGAC 96                            SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGC1 44                           ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         TCACCTCACCATACCGCACTCAGGCAAGCCATTCTCTGCTGGGGGGAA192                            Ser ProHisHisThrAlaLeuArgGlnAlaIleLeuCysTrpGlyGlu                              505560                                                                         TTGATGACTCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCA240                            LeuMetThrLe uAlaThrTrpValGlyAsnAsnLeuGluAspProAla                              65707580                                                                       TCAAGGGACCTAGTAGTCAATTATGGTAATACTAACATGGGTTTAAAA288                            SerArgA spLeuValValAsnTyrGlyAsnThrAsnMetGlyLeuLys                              859095                                                                         ATTAGGCAACTATTGTGGTTTCATATATCTTGCCTTACTTTTGGAAGA336                            IleArg GlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                              100105110                                                                      GAGACTGTACTTGAATATTTGGTCTCTTTCGGAGTGTGGATTCGCACT384                            GluThrVal LeuGluTyrLeuValSerPheGlyValTrpIleArgThr                              115120125                                                                      CCTCCAGCCTATAGACCACCAAATGCCCCTATCTTATCAACACTTCCG432                            ProProAlaTyrAr gProProAsnAlaProIleLeuSerThrLeuPro                              130135140                                                                      GAAACTACTGTTGTTAGACGACGGGACCGAGGCAGGTCCCCTAGAAGA480                            GluThrThrValValArgArgA rgAspArgGlyArgSerProArgArg                              145150155160                                                                   AGAACTCCCTCGCCTCGCAGACGCAGATCTCAATCGCCGCGTCGCAGA528                            ArgThrProSerProArg ArgArgArgSerGlnSerProArgArgArg                              165170175                                                                      AGATCTCAATCTCGGGAATCTCAATGTTAG558                                              ArgSerGlnSerArgGlu SerGlnCys                                                   180185                                                                         (2) INFORMATION FOR SEQ ID NO:8:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 185 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                        MetAlaIleAspProTyrLysGluPheGl yAlaThrValGluLeuLeu                              151015                                                                         SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               2025 30                                                                        ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         SerProHisHisThrAlaLeuArgGlnAlaIleLeuCysTrpGlyGlu                                505560                                                                        LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       SerArgAspLeuValVal AsnTyrGlyAsnThrAsnMetGlyLeuLys                              859095                                                                         IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100 105110                                                                     GluThrValLeuGluTyrLeuValSerPheGlyValTrpIleArgThr                               115120125                                                                      ProProAlaTyrArgProProAsnAlaProIleLeuSerTh rLeuPro                              130135140                                                                      GluThrThrValValArgArgArgAspArgGlyArgSerProArgArg                               145150155160                                                                   ArgThr ProSerProArgArgArgArgSerGlnSerProArgArgArg                              165170175                                                                      ArgSerGlnSerArgGluSerGlnCys                                                    180185                                                                         (2) INFORMATION FOR SEQ ID NO:9:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 558 base pairs                                                     (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..558                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                        ATGGCTATTGACCCTTATAAAGAATTTGGAGCT ACTGTGGAGTTACTC48                            MetAlaIleAspProTyrLysGluPheGlyAlaThrValGluLeuLeu                               151015                                                                         TCGTTTTTGCCTTCTGACTTCTTTCCTTCCGTC AGAGATCTCCTAGAC96                            SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTC TCCTGAGCATTGC144                           ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         TCACCTCACCATACCGCACTCAGGCAAGCCATTCTCTGCT GGGGGGAA192                           SerProHisHisThrAlaLeuArgGlnAlaIleLeuCysTrpGlyGlu                               505560                                                                         TTGATGACTCTAGCTACCTGGGTGGGTAATAATTTGGAAGATCCAGCA 240                           LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       TCAAGGGACCTAGTAGTCAATTATGTTAATACTAACATGGGTTTA AAA288                           SerArgAspLeuValValAsnTyrValAsnThrAsnMetGlyLeuLys                               859095                                                                         ATTAGGCAACTATTGTGGTTTCATATATCTTGCCTTACTTTTGG AAGA336                           IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100105110                                                                      GAGACTGTACTTGAATATTTGGCCTCTTTCGGAGTGTGGATTCGCA CT384                           GluThrValLeuGluTyrLeuAlaSerPheGlyValTrpIleArgThr                               115120125                                                                      CCTCCAGCCTATAGACCACCAAATGCCCCTATCTTATCAACACTTCCG 432                           ProProAlaTyrArgProProAsnAlaProIleLeuSerThrLeuPro                               130135140                                                                      GAAACTACTGTTGTTAGACGACGGGACCGAGGCAGGTCCCCTAGAAGA480                            GluT hrThrValValArgArgArgAspArgGlyArgSerProArgArg                              145150155160                                                                   AGAACTCCCTCGCCTCGCAGACGCAGATCTCAATCGCCGCGTCGCAGA528                             ArgThrProSerProArgArgArgArgSerGlnSerProArgArgArg                              165170175                                                                      AGATCTCAATCTCGGGAATCTCAATGTTAG558                                               ArgSerGlnSerArgGluSerGlnCys                                                   180185                                                                         (2) INFORMATION FOR SEQ ID NO:10:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 185 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                                       MetAlaIleAs pProTyrLysGluPheGlyAlaThrValGluLeuLeu                              151015                                                                         SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               20 2530                                                                        ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         SerProHisHisThrAlaLeuArgGlnAlaIleL euCysTrpGlyGlu                              505560                                                                         LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                        SerArgAspLeuValValAsnTyrValAsnThrAsnMetGlyLeuLys                              859095                                                                         IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                                100105110                                                                     GluThrValLeuGluTyrLeuAlaSerPheGlyValTrpIleArgThr                               115120125                                                                      ProProAlaTyrArgProProAs nAlaProIleLeuSerThrLeuPro                              130135140                                                                      GluThrThrValValArgArgArgAspArgGlyArgSerProArgArg                               145150155 160                                                                  ArgThrProSerProArgArgArgArgSerGlnSerProArgArgArg                               165170175                                                                      ArgSerGlnSerArgGluSerGlnCys                                                    180 185                                                                        (2) INFORMATION FOR SEQ ID NO:11:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 645 base pairs                                                     (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                           (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 1..645                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                                       ATGGCTATTGACCCTT ATAAAGAATTTGGAGCTACTGTGGAGTTACTC48                            MetAlaIleAspProTyrLysGluPheGlyAlaThrValGluLeuLeu                               151015                                                                         TCGTTTTTGCCTTCT GACTTCTTTCCTTCCGTCAGAGATCTCCTAGAC96                            SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               202530                                                                         ACCGCCTCAGCTCTGTAT CGGGAAGCCTTAGAGTCTCCTGAGCATTGC144                           ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         TCACCTCACCATACCGCACTCAG GCAAGCCATTCTCTGCTGGGGGGAA192                           SerProHisHisThrAlaLeuArgGlnAlaIleLeuCysTrpGlyGlu                               505560                                                                         TTGATGACTCTAGCTACCTGGGTGGGTAATA ATTTGGAAGATCCAGCA240                           LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       TCAAGGGACCTAGTAGTCAATTATGTT AATACTAACATGGGTTTAAAA288                           SerArgAspLeuValValAsnTyrValAsnThrAsnMetGlyLeuLys                               859095                                                                         ATTAGGCAACTATTGTGGTTTCATATA TCTTGCCTTACTTTTGGAAGA336                           IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100105110                                                                      GAGACTGTACTTGAATATTTGGTCTCTTT CGGAGTGTGGATTCGCACT384                           GluThrValLeuGluTyrLeuValSerPheGlyValTrpIleArgThr                               115120125                                                                      CCTCCAGCCTATAGACCACCAAATGCCCCTATCT TATCAACACTTCCG432                           ProProAlaTyrArgProProAsnAlaProIleLeuSerThrLeuPro                               130135140                                                                      GAAACTACTGTTGTTAGACGACGGACCGAGGCAGGTCCCCTA GAAGAA480                           GluThrThrValValArgArgArgThrGluAlaGlyProLeuGluGlu                               145150155160                                                                   GAACTCCCTCGCCTCGCAGACGCAGATCTCAATCGCCGC GTCGCAGAA528                           GluLeuProArgLeuAlaAspAlaAspLeuAsnArgArgValAlaGlu                               165170175                                                                      GATCTCAATCTCGGGAATCTCAATGTTAGAAGCTTCCG ACAAAACCGC576                           AspLeuAsnLeuGlyAsnLeuAsnValArgSerPheArgGlnAsnArg                               180185190                                                                      CTACTCTCTTCTAAAAGTCGGACTATGTCTAATTTAGTCT TGCGTCTT624                           LeuLeuSerSerLysSerArgThrMetSerAsnLeuValLeuArgLeu                               195200205                                                                      CGCCAGACTATTTTGTCTTAA 645                                                      ArgGlnThrIleLeuSer                                                             210215                                                                         (2) INFORMATION FOR SEQ ID NO:12:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 214 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                                       MetAlaIleAspProTy rLysGluPheGlyAlaThrValGluLeuLeu                              151015                                                                         SerPheLeuProSerAspPhePheProSerValArgAspLeuLeuAsp                               20 2530                                                                        ThrAlaSerAlaLeuTyrArgGluAlaLeuGluSerProGluHisCys                               354045                                                                         SerProHisHisThrAlaLeuArgGlnAlaIleLeuCysT rpGlyGlu                              505560                                                                         LeuMetThrLeuAlaThrTrpValGlyAsnAsnLeuGluAspProAla                               65707580                                                                       SerArg AspLeuValValAsnTyrValAsnThrAsnMetGlyLeuLys                              859095                                                                         IleArgGlnLeuLeuTrpPheHisIleSerCysLeuThrPheGlyArg                               100 105110                                                                     GluThrValLeuGluTyrLeuValSerPheGlyValTrpIleArgThr                               115120125                                                                      ProProAlaTyrArgProProAsnAlaPr oIleLeuSerThrLeuPro                              130135140                                                                      GluThrThrValValArgArgArgThrGluAlaGlyProLeuGluGlu                               145150155 160                                                                  GluLeuProArgLeuAlaAspAlaAspLeuAsnArgArgValAlaGlu                               165170175                                                                      AspLeuAsnLeuGlyAsnLeuAsnValArgSerPheArgGlnAsnArg                                180185190                                                                     LeuLeuSerSerLysSerArgThrMetSerAsnLeuValLeuArgLeu                               195200205                                                                      ArgGlnThrIleLeuSer                                                             210                                                                            (2) INFORMATION FOR SEQ ID NO:13:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 10 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                                       AACAGAATTC10                                                                   (2) INFORMATION FOR SEQ ID NO:14:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 8 base pairs                                                       (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                                       AACAGACC8                                                                      (2) INFORMATION FOR SEQ ID NO:15:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 25 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                                       GGCCATGGACATTGACCCTTATAAA25                                                    (2) INFORMATION FOR SEQ ID NO:16:                                              ( i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 34 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                                       GGCCATGGTCATTGACCCTTATAAAGAATTTGGA34                                           (2) INFORMATION FOR SEQ ID NO:17:                                              (i) SEQUENCE CHARACTERISTICS:                                                   (A) LENGTH: 29 base pairs                                                     (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:                                       CCGAATTCATGGACATTGACCCTTATAAA29                                                (2) INFORMATION FOR SEQ ID NO:18:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 29 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:                                       CCGAATTCATGGTCATTGACCCTTATAAA29                                                (2) INFORMATION FOR SEQ ID NO:19:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 30 base pairs                                                       (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:                                       CGGAATTCGATGGACATTGACCCTTATAAA30                                               (2) INFORMATION FOR SEQ ID NO:20:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 31 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:                                       CGGAATTCGGATGGACATTGACCCTTATAAA31                                              (2) INFORMATION FOR SEQ ID NO:21:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 32 base pairs                                                      (B) TYPE: nucleic acid                                                          (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:                                       CGGAATTCGGAATGGACATTGACCCTTATAAA32                                             (2) INFORMATION FOR SEQ ID NO:22:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 33 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                        (D) TOPOLOGY: linear                                                          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:                                       CGGAATTCGGATATGGACATTGACCCTTATAAA33                                            (2) INFORMATION FOR SEQ ID NO:23:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 35 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D ) TOPOLOGY: linear                                                          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:                                       CGGGAATTCGGATCATGGACATTGACCCTTATAAA35                                          (2) INFORMATION FOR SEQ ID NO:24:                                              (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 44 base pairs                                                      (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                            (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:                                      GGAAGCTTCTAACATTGAGATTCCCGAGATTGAGATCTTCTGCG44                             

What is claimed is:
 1. A vector comprising a DNA molecule having a sequence consisting essentially of Sequence ID No: 3, Sequence ID No: 5, Sequence ID No: 7, Sequence ID No: 9, or Sequence ID No:
 11. 2. The vector of claim 1 in which said sequences further comprises about an 8 to 20 base pair spacer before the initiation codon.
 3. The vector of claim 2 in which said spacer consists essentially of Sequence ID No:
 13. 4. The vector of claim 2 in which said spacer consists essentially of Sequence ID No:
 14. 5. The vector of claim 1 in which the second codon of said sequence is a host preferred codon.
 6. The vector of claim 2 in which the second codon of said sequence is a host preferred codon.
 7. The vector of claim 3 in which the second codon of said sequence is a host preferred codon.
 8. The vector of claim 4 in which the second codon of said sequence is a host preferred codon.
 9. The vector of claim 5 in which said host preferred codon is an E. coli preferred codon.
 10. The vector of claim 6 in which said host preferred codon is an E. coli preferred codon.
 11. The vector of claim 7 in which said host preferred codon is an E. coli preferred codon.
 12. The vector of claim 8 in which said host preferred codon is an E. coli preferred codon.
 13. A host transformed with a vector comprising a DNA molecule having the sequence consisting essentially of Sequence ID No: 3, Sequence ID No: 5, Sequence ID No: 7, Sequence ID No: 9, or Sequence ID No:
 11. 14. The host of claim 13 in which the vector further comprises about an 8 to 20 base pair spacer before the initiation codon of said sequences.
 15. The host of claim 14 in which said spacer consists essentially of Sequence ID No:
 13. 16. The host of claim 14 in which said spacer consists essentially of Sequence ID No.
 14. 17. The host of claim 13 in which the second codon of said sequences are host preferred codons.
 18. The host of claim 14 in which the second codon of said sequences are host preferred codons.
 19. The host of claim 15 in which the second codon of said sequences are host preferred codons.
 20. The host of claim 16 in which the second codon of said sequences are host preferred codons.
 21. The host of claim 13 which is E. coli.
 22. The host of claim 14 which is E. coli.
 23. The host of claim 15 which is E. coli.
 24. The host of claim 16 which is E. coli. 